Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.
View Plans2-year trend showing gross, operating, and net profit margins
Glaxosmithkline Pharmaceuticals Ltd.'s net profit margin of 23.8% in FY2025 reflects excellent profitability, with operating margin at 32.3% and gross margin at 64.3%.
In FY 2025, Glaxosmithkline Pharmaceuticals Ltd. posted a gross margin of 64.3%, an operating margin of 32.3%, a net margin of 23.8%. Gross Margin = (Revenue - COGS) / Revenue; Operating Margin = EBIT / Revenue; Net Margin = Net Income / Revenue. Typical healthy ranges: Gross 20-40%, Operating 10-20%, Net 5-10%+. Consistent or improving margins indicate strong competitive positioning.
2-year trend showing revenue, gross profit, and net profit
Glaxosmithkline Pharmaceuticals Ltd.'s revenue grew 8.9% to 38.95B and net profit grew 57.2% to 9.28B YoY in FY2025, indicating moderate business momentum.
In FY 2025, Glaxosmithkline Pharmaceuticals Ltd.'s revenue grew by 8.9% year-over-year. Revenue is total income from operations. Gross Profit is revenue minus cost of goods. Net Profit is the bottom line after all expenses. Consistent growth across all three signals a healthy, expanding business.
2-year trend showing shareholder returns
Glaxosmithkline Pharmaceuticals Ltd.'s ROE of 47.5% in FY2025 indicates excellent capital efficiency.
In FY 2025, Glaxosmithkline Pharmaceuticals Ltd. reported an ROE of 47.5%. ROE = (Net Income / Shareholders' Equity) x 100. Measures how efficiently the company turns equity into profit. Above 15% is generally strong; above 25% is excellent. Very high ROE may signal high leverage — check alongside debt levels.
2-year trend comparing profitability with cash generation
Glaxosmithkline Pharmaceuticals Ltd.'s FCF/NI ratio of 1.37x in FY2025 indicates high-quality, cash-backed earnings.
In FY 2025, Glaxosmithkline Pharmaceuticals Ltd.'s free cash flow exceeded net income. Free Cash Flow = Operating Cash Flow - Capital Expenditure. When FCF exceeds net income, it suggests high-quality, cash-backed earnings. Persistent gaps may indicate aggressive accounting or heavy capex needs.
2-year trend comparing profitability with cash from operations
Glaxosmithkline Pharmaceuticals Ltd.'s OCF/NI ratio of 1.39x in FY2025 indicates strong cash collection and working capital efficiency.
In FY 2025, Glaxosmithkline Pharmaceuticals Ltd.'s operating cash flow exceeded net income. Operating Cash Flow is the actual cash from core operations. OCF exceeding net income signals strong cash collection. OCF trailing net income may indicate aggressive revenue recognition or working capital issues.
Measure a company's financial leverage, liquidity, and ability to meet financial obligations.
2-year trend showing short-term liquidity position
Glaxosmithkline Pharmaceuticals Ltd.'s current ratio of 1.79x in FY2025 indicates healthy short-term liquidity.
In FY 2025, Glaxosmithkline Pharmaceuticals Ltd. reported a current ratio of 1.79. Current Ratio = Current Assets / Current Liabilities. Measures short-term liquidity. A ratio of 1.5-3.0 is generally healthy; below 1.0 signals liquidity risk; above 3.0 may indicate underutilized assets.
2-year trend showing ability to service debt
Glaxosmithkline Pharmaceuticals Ltd.'s interest coverage ratio of 959.2x in FY2025 indicates comfortable debt servicing capacity.
In FY 2025, Glaxosmithkline Pharmaceuticals Ltd. reported an interest coverage ratio of 959.2x. Interest Coverage = EBIT / Interest Expense. Shows how many times operating profit covers interest payments. Above 5x is comfortable; below 1.5x signals potential difficulty servicing debt.
2-year trend showing financial leverage and capital structure
Glaxosmithkline Pharmaceuticals Ltd.'s debt-to-equity ratio of 0.01x in FY2025 reflects a conservative, low-leverage capital structure.
In FY 2025, Glaxosmithkline Pharmaceuticals Ltd. reported a debt-to-equity ratio of 0.01. Debt-to-Equity = Total Debt / Total Equity. Below 1.0 is conservative; 1.0-2.0 is moderate; above 2.0 indicates higher financial risk. Capital-intensive industries naturally carry higher ratios.
2-year trend showing total debt with year-over-year changes
Glaxosmithkline Pharmaceuticals Ltd.'s debt decreased 46.7% YoY in FY2025 — positive deleveraging improves financial flexibility.
In FY 2025, Glaxosmithkline Pharmaceuticals Ltd.'s total debt decreased by 46.7% year-over-year. Total Debt includes short-term debt, long-term loans, debentures, and capital leases. YoY changes (shown as percentages) reveal whether the company is leveraging up or deleveraging.
Year-over-year change in diluted shares outstanding
Glaxosmithkline Pharmaceuticals Ltd.'s diluted shares remained virtually unchanged in FY2025.
Over 2 years (FY2024–FY2025), diluted shares remained essentially unchanged at 169.39M.
In FY 2025, Glaxosmithkline Pharmaceuticals Ltd.'s diluted shares increased by 0.0% year-over-year. Diluted Shares accounts for stock options, warrants, and convertibles. Positive YoY change means dilution (red); negative means buybacks (green). Consistent dilution above 5% annually is a red flag.
You're viewing 2 years of data. Upgrade to access 10 years of financial ratios, margins, and performance metrics.
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: FY 2025